These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 21432755)

  • 1. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
    Hefke T; Zittermann A; Fuchs U; Schulte-Eistrup S; Gummert JF; Schulz U
    Thorac Cardiovasc Surg; 2012 Feb; 60(1):26-34. PubMed ID: 21432755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension.
    Perez-Villa F; Cuppoletti A; Rossel V; Vallejos I; Roig E
    Clin Transplant; 2006; 20(2):239-44. PubMed ID: 16640533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan in heart transplantation candidates with severe pulmonary hypertension: efficacy, safety and outcome after transplantation.
    Perez-Villa F; Farrero M; Cardona M; Castel MA; Tatjer I; Penela D; Vallejos I
    Clin Transplant; 2013; 27(1):25-31. PubMed ID: 22861120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment.
    Dandel M; Lehmkuhl HB; Mulahasanovic S; Weng Y; Kemper D; Grauhan O; Knosalla C; Hetzer R
    J Heart Lung Transplant; 2007 Sep; 26(9):898-906. PubMed ID: 17845928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
    Hirono K; Yoshimura N; Taguchi M; Watanabe K; Nakamura T; Ichida F; Miyawaki T
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):346-51. PubMed ID: 20434177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.
    LaRue SJ; Garcia-Cortes R; Nassif ME; Vader JM; Ray S; Ravichandran A; Rasalingham R; Silvestry SC; Ewald GA; Wang IW; Schilling JD
    Cardiovasc Ther; 2015 Apr; 33(2):50-5. PubMed ID: 25759010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.
    D'Alto M; Romeo E; Argiento P; Santoro G; Sarubbi B; Gaio G; Mélot C; Russo MG; Naeije R; Calabrò R
    Heart; 2010 Sep; 96(18):1475-9. PubMed ID: 20668108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of pulmonary hypertension on outcomes of patients with low left ventricular ejection fraction: a propensity analysis.
    Yang C; Li D; Mennett R; Hammond J; Zhang G; Chen D; Lundbye J; Gallagher R
    J Heart Valve Dis; 2012 Nov; 21(6):767-73. PubMed ID: 23409360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.
    Karavolias GK; Georgiadou P; Gkouziouta A; Kariofillis P; Karabela G; Tsiapras D; Sbarouni E; Chaidaroglou A; Degiannis D; Adamopoulos S; Voudris V
    Expert Opin Ther Targets; 2010 Dec; 14(12):1283-9. PubMed ID: 20958219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control study.
    Reichenbach A; Al-Hiti H; Malek I; Pirk J; Goncalvesova E; Kautzner J; Melenovsky V
    Int J Cardiol; 2013 Sep; 168(1):60-5. PubMed ID: 23058346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K; Jakrapanichakul D; Sompradikul S
    J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.
    Givertz MM; Hare JM; Loh E; Gauthier DF; Colucci WS
    J Am Coll Cardiol; 1996 Dec; 28(7):1775-80. PubMed ID: 8962566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.
    Sitbon O; Gressin V; Speich R; Macdonald PS; Opravil M; Cooper DA; Fourme T; Humbert M; Delfraissy JF; Simonneau G
    Am J Respir Crit Care Med; 2004 Dec; 170(11):1212-7. PubMed ID: 15317666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case report.
    Mogollón MV; Lage E; Cabezón S; Hinojosa R; Ballesteros S; Aranda A; Sobrino JM; Ordóñez A
    Transplant Proc; 2006 Oct; 38(8):2522-3. PubMed ID: 17097987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.